Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Importantly, there were no reports of pancreatitis, medullary thyroid carcinoma, or other severe adverse events associated with the peptide during the Phase 2 trial
Data availability No datasets were generated or analysed during the current study
Understanding proper medication handling applies across different treatments
Benefits (Research Focus) GLP-1 receptor agonism studied for selective activation of the GLP-1 receptor with downstream insulin and glucagon regulation Glycemic control research investigated for fasting glucose, HbA1c, and insulin sensitivity parameters in T2D models Body composition examined for fat-mass and lean-mass partitioning in DIO and obesity models Appetite and gastric pathways explored for satiety signaling and delayed gastric emptying endpoints Long-acting profile C18 fatty diacid albumin-binding chemistry for extended half-life (~7 days) What Researchers Look At GLP-1 receptor binding affinity, cAMP activation, and -arrestin recruitment Food intake, body weight, and adipose-tissue change in DIO rodent models Pancreatic -cell function and insulinotropic response endpoints Gastric emptying time and gastrointestinal transit profiles Comparative pharmacology versus tirzepatide, retatrutide, and other incretin analogs Quick Specs Form: Lyophilized white powder Net Peptide Content: 10 mg per vial Quantity: 1 vial Appearance: White to off-white lyophilizate Reconstitution: Bacteriostatic or sterile water (added by the end researcher) Purity: 99% by HPLC Identity: MS-verified (per COA) Storage: Protect from light Identity Basics Compound: Semaglutide Synonyms: NN9535
If a prescription is issued, the medication is prepared by one of Sprout Health's partner compounding pharmacies and shipped to the consumer
US$ 21.96
US$ 27.63
US$ 28.23
